Balaji Prasad
Stock Analyst at Barclays
(3.33)
# 1,012
Out of 4,964 analysts
132
Total ratings
48.31%
Success rate
2.81%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $7.62 | +228.08% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $9.36 | +17.52% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $26.11 | -8.06% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $10.42 | -13.63% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $124.43 | +60.73% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $18.49 | +2.76% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $57.82 | +3.77% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $155.37 | +57.04% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $9.20 | +160.87% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $32.20 | -31.68% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $640.86 | -18.86% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $18.05 | +44.04% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $14.24 | +19.38% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $8.03 | +124.16% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $3.42 | +192.40% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.14 | +514.04% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $7.62
Upside: +228.08%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $9.36
Upside: +17.52%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $26.11
Upside: -8.06%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $10.42
Upside: -13.63%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $124.43
Upside: +60.73%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $18.49
Upside: +2.76%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $57.82
Upside: +3.77%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $155.37
Upside: +57.04%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $9.20
Upside: +160.87%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $32.20
Upside: -31.68%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $640.86
Upside: -18.86%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $18.05
Upside: +44.04%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $14.24
Upside: +19.38%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $8.03
Upside: +124.16%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $3.42
Upside: +192.40%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.14
Upside: +514.04%